Please login to the form below

Not currently logged in
Email:
Password:

Biogen bulks up in Alzheimer’s again with $2.7bn Sangamo deal

Gains rights to tau-targeting drug ST-501 as part of broader alliance

Alzheimer's

Biogen has made another big investment play in Alzheimer’s disease, penning a $350m upfront agreement with gene-editing specialist Sangamo for rights to tau-targeting drug ST-501 as part of a broader R&D alliance.

The tie-up also covers a second drug called ST-502 – in development for Parkinson’s disease and other neurodegenerative diseases characterised by the abnormal clumping of alpha-synuclein protein (synucleinopathies) – as well as a third unnamed candidate for a neuromuscular disease. Biogen also claims exclusive rights to nine additional undisclosed neurological targets.

The deal is sizeable considering both ST-501 and ST-502 are still in preclinical development, with the upfront payment – split between $125m in cash and $225m in new Sangamo stock – backed up by $2.37bn in milestones tied to development, regulatory, and commercial targets.

Tau is emerging as a target for drug development in Alzheimer’s as well as other disorders like frontotemporal dementia.

The licensing deal comes as Biogen prepares to file its amyloid-targeting Alzheimer’s therapy aducanumab, which had been written off last year after disappointing clinical trial results but was resurrected after it appeared to show a benefit on longer-term follow-up.

Sangamo’s specialises in the development of gene-editing drugs based on its zinc finger nuclease (ZFN) technology, which can be used to regulate the expression of genes but had disappointing results in a mucopolysaccharidosis type II trial last year.

Biogen’s deal is an endorsement of the technology platform at a time when rival gene-editing technologies like CRISPR/Cas9 seem to be gathering momentum, with encouraging preliminary results from  trial of Vertex and CRISPR Therapeutics’ CTX001 in blood disorders last November.

“As a pioneer in neuroscience, Biogen will collaborate with Sangamo on a new gene regulation therapy approach, working at the DNA level, with the potential to treat challenging neurological diseases of global significance,” said Al Sandrock, Biogen’s head of R&D.

Sangamo’s zinc finger protein transcription factor (ZFP-TF) approach involves introducing double-stranded DNA breaks engineered to target specific sequences in a cell.

The cell tries to fix the break using another copy of the sequence as a backup, such as the other unbroken chromosome in the pair but – by supplying a new template using an adeno-associated virus (AAV) vector – the system can be forced to insert a desired sequence instead.

“Highly specific, potent, and tunable repression of tau and alpha synuclein has been demonstrated in preclinical studies using AAV vectors to deliver tau-targeted (ST-501) and alpha synuclein-targeted (ST-502) ZFP-TFs,” according to the partners.

Sangamo also has a gene therapy platform, with a first candidate for haemophilia A heading for late-stage development at partner Pfizer later this year.

Article by
Phil Taylor

28th February 2020

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics